AspCOVID-19 study: fungal infection of the airways in severe COVID-19 pneumonia

Not Applicable

Completed

• Conditions: COVID-19 (SARS-CoV-2 infection) related pneumonia; Infections and Infestations

• Registration Number: ISRCTN14810048
• Lead Sponsor: Klinikum der Universität München

Brief Summary

2020 non-peer-reviewed results in preprint https://doi.org/10.1101/2020.07.21.20158972 (added 17/03/2021) 2021 results in https://pubmed.ncbi.nlm.nih.gov/33730058/ (added 16/04/2021)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-07-31
• Study Start: 2020-11-17
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

Critically ill patients with severe COVID-19 pneumonia

Exclusion Criteria

1. Younger than 18 years old
2. Pregnancy
3. Missed informed consent

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary aspergillosis infection measured using the galactomannan from serum and broncho-alveolar lavage on day 1, 3, 7, 10, 14 and then every three days after ICU admission and intubation/mechanical ventilation

Secondary Outcome Measures

Name	Time	Method
<br> 1. Duration of ICU stay measured using patient records<br> 2. Mortality rate measured using patient records<br> 3. Co-Infections measured using patient records<br> 4. Ventilation time measured using patient records<br> 5. Duration of hospital stay measured using patient records<br>